I tried several hours ago and the issue was gobbled up on a technicality. The results suggest some potential as a treatment but they MEASURE its use as a prophylactic...in healthy subjects.
That is a good point which I overlooked when I read the PR. I do not believe the purpose of the test was to do anything other than to show an antiviral effect. It should not predict a preventive or prophylaxis benefit but I would be happy to have someone with more experience to correct me.
I was expecting the test to performed on infected cells with Brilacicin introduced after the infected cells had incubated.
There are a number of different ways to test for an antiviral effect.
There are a lot of questions that still need answering. And, I agree about the likelyhood of quick follow-up testing.
Message in reply to:
There definitely will be quick follow-up to this with next steps. I expect Leo to keep this in front of everyone for a while...
Another point not really being discussed. The graphic shows B's potential as a prophylactic. B was introduced to the cell cultures BEFORE the virus and the viral load was compared later. The higher dose of B reduced viral load by about 50% if I'm reading it correctly. I wonder what would happen if B was introduced AFTER infection....